首页> 外文期刊>Indian heart journal >The role of polysaccharide peptide of Ganoderma lucidum as a potent antioxidant against atherosclerosis in high risk and stable angina patients
【24h】

The role of polysaccharide peptide of Ganoderma lucidum as a potent antioxidant against atherosclerosis in high risk and stable angina patients

机译:灵芝多糖肽在高危和稳定型心绞痛患者中作为有效的抗动脉粥样硬化抗氧化剂的作用

获取原文
           

摘要

Objectives Antioxidants can reduce oxidative radicals that affect the early phase of atherogenesis, that is endothelial dysfunction. Polysaccharide Peptide (PsP) derived from Ganoderma lucidum has an active substance in the form of β-glucan. Previous studies have proven the PsP of Ganoderma lucidum as an effective antioxidant in atherosclerotic rats and shows no toxicity in animal model. This study aims to prove the effect of PsP as potent antioxidant in high risk and stable angina patients. Method This is a clinical trial conducted to 37 high risk and 34 stable angina patients, which were determined based on ESC Stable CAD Guidelines and Framingham risk score, with pre and post test design without control group. The parameters are superoxide dimustase (SOD) and malondialdehyde (MDA) concentration, circulating endothelial cell (CEC) and endothelial progenitor cell (EPC) counts. The patients were given PsP 750 mg/day in 3 divided dose for 90 days. Paired t -test was performed for normally distributed data, and Wilcoxon test for not normally distributed data, and significant level of p ≤ 0,05. Results SOD level in high risk patients slightly increased but not statistically significant with p = 0,22. Level of SOD in stable angina group significantly increased with p = 0,001. MDA concentration significantly reduced in high risk and stable angina patients with p = 0.000. CEC significantly reduced both in high risk and stable angina patients, with p = 0.000 in both groups. EPC count significantly reduced in high risk and stable angina with p = 0.000. Conclusion PsP of Ganoderma lucidum is a potent antioxidant against pathogenesis of atherosclerosis in stable angina and high risk patients.
机译:目的抗氧化剂可以减少影响动脉粥样硬化早期阶段的氧化自由基,即内皮功能障碍。源自灵芝的多糖肽(PsP)具有β-葡聚糖形式的活性物质。先前的研究已经证明灵芝的PsP是动脉粥样硬化大鼠的有效抗氧化剂,并且在动物模型中未显示毒性。这项研究旨在证明PsP作为强效抗氧化剂在高风险和稳定型心绞痛患者中的作用。方法这是一项针对37例高危和34例稳定型心绞痛患者的临床试验,这些患者是根据ESC稳定CAD指南和Framingham风险评分确定的,试验前和试验后均没有对照组。参数是超氧化物歧化酶(SOD)和丙二醛(MDA)浓度,循环内皮细胞(CEC)和内皮祖细胞(EPC)计数。患者分三天服用PsP 750 mg /天,共90天。对正态分布数据进行配对t检验,对非正态分布数据进行Wilcoxon检验,p≤0.05的显着水平。结果高危患者的SOD水平略有升高,但无统计学意义,p = 0.22。稳定型心绞痛组的SOD水平显着升高,p = 0,001。高危和稳定型心绞痛患者的MDA浓度显着降低,p = 0.000。高危和稳定型心绞痛患者的CEC均明显降低,两组均p = 0.000。在高风险和稳定型心绞痛中,EPC计数显着降低,p = 0.000。结论灵芝的PsP是稳定型心绞痛和高危患者的一种有效的抗动脉粥样硬化发病机理的抗氧化剂。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号